Search research articles
Contact Us
Filters
Showing results (21-30 of 41) with videos related to
Page
of 5
Sort By:
American Journal of Clinical Oncology
|
June 1, 1991
Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study
F Roila, E Boschetti, M Tonato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2013
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial
G Procopio, E Verzoni, S Bracarda, et al.
British Journal of Cancer
|
March 31, 2011
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
G Procopio, E Verzoni, S Bracarda, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Reliability and validity of a quality of life questionnaire in cancer patients
E Ballatori, F Roila, C Basurto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1989
Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research
F Roila, M Tonato, C Basurto, et al.
Journal of Endocrinological Investigation
|
April 24, 2012
Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma
A Ferrero, P Sperone, A Ardito, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer
A Ardizzoni, M Venturini, L Crinò, et al.
British Journal of Cancer
|
March 24, 2012
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
S Bracarda, T E Hutson, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 15, 2008
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma
B Melichar, P Koralewski, A Ravaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2011
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
J Beck, G Procopio, E Bajetta, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 41) with videos related to
Sort By:
Page
of 5
American Journal of Clinical Oncology
|
June 1, 1991
Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study
F Roila, E Boschetti, M Tonato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2013
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial
G Procopio, E Verzoni, S Bracarda, et al.
British Journal of Cancer
|
March 31, 2011
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
G Procopio, E Verzoni, S Bracarda, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Reliability and validity of a quality of life questionnaire in cancer patients
E Ballatori, F Roila, C Basurto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1989
Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research
F Roila, M Tonato, C Basurto, et al.
Journal of Endocrinological Investigation
|
April 24, 2012
Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma
A Ferrero, P Sperone, A Ardito, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer
A Ardizzoni, M Venturini, L Crinò, et al.
British Journal of Cancer
|
March 24, 2012
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
S Bracarda, T E Hutson, C Porta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 15, 2008
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma
B Melichar, P Koralewski, A Ravaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2011
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
J Beck, G Procopio, E Bajetta, et al.
Page
of 5